News
Galapagos’ GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study
Date: 22/11/2011
Mechelen, Belgium - Galapagos reports that its JAK1 inhibitor GLPG0634 shows excellent efficacy and safety in a Phase II clinical study in rheumatoid arthritis patients. See the press release here.